Peptide·plain sequence-like

Lanreotide

ATLPC0027686

Routes

Compare in workbench Download release API JSON

Coveragecounts only · not riskATLPC0027686

Measurements
20
Endpoints
7
Domains
3/5
Products
1

No matrix stability evidence
5 clearance measurements
2 immunogenicity context entries
No sequence liability cues

Jump to domain

Open the matching evidence section below

All evidence index · 20

Exposure / Absorption

13 measurements

Distribution / Barrier

2 measurements

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

5 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

No reviewed sequence representation available

This peptide currently has identity-level evidence, but no reviewed sequence, HELM, or SMILES representation for residue-level interpretation.

Structure & chemistry

Chemical representationnone

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

Not available

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modifications1 signal

Feature	Positions	Interpretation	Link
Form-level topology	ATLPF0028678	Disulfide-constrained form. Residue-level connection endpoints are shown separately when available.	Not linked

Exposure / Absorption

13 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability Tmax Cmax AUC

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability4 records · 0 matched-context · 4 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Route: SC · 40 · Lanreotide · exact product name match · field mismatch · Source: Primary reference linked	Source record
2	78.4 %	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 120mg · After a single, de... · Source: Primary reference linked	Reference
3	73.4 %	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 60mg · After a single, dee... · Source: Primary reference linked	Reference
4	69 %	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 90mg · After a single, dee... · Source: Primary reference linked	Reference

AUC2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Single-dose linearity was demonstrated with respect to AUC and C max , and showed high inter-subject variability.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · cmax auc single dose linearity variability text · Sin... · Source: Primary reference linked	Reference
2	Observation An approximate 2-fold decrease in total serum clearance of lanreotide, with a consequent 2-fold increase in half-life and AUC was observed.	Interpret as reported	human · serum	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment auc change text · An appr... · Source: Primary reference linked	Reference

Cmax5 records · 0 matched-context · 5 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Single-dose linearity was demonstrated with respect to AUC and C max , and showed high inter-subject variability.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · cmax auc single dose linearity variability text · Sin... · Source: Primary reference linked	Reference
2	4.3-8.4 ng/mL	Use only explicitly reported fields	human	Result: Interval measurement · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · cmax mean range · Mean C max values ranged from 4.3 t... · Source: Primary reference linked	Reference
3	7.7 ng/mL	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 120mg · At steady state,... · Source: Primary reference linked	Reference
4	3.8 ng/mL	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 60mg · At steady state,... · Source: Primary reference linked	Reference
5	5.7 ng/mL	Use only explicitly reported fields	human	Result: Reported point value · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 90mg · At steady state,... · Source: Primary reference linked	Reference

Tmax2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	<= 1 day <= 86400 seconds	Interpret as reported	human	Result: Upper-bound measurement · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide repeat dose tmax within first day · Acrome... · Source: Primary reference linked	Reference
2	<= 1 day <= 86400 seconds	Interpret as reported	human	Result: Upper-bound measurement · Molecular form: ATLPF0028678 · Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide single dose tmax within first day · After... · Source: Primary reference linked	Reference

Distribution / Barrier

2 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	16.1 L	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Result: Reported point value · Molecular form: ATLPF0028678 · Route: intravenous · Dose/window: healthy volunteers after intravenous administration · Time: steady state · Source: Primary reference linked	Reference

Plasma protein binding1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	79-83 %	Eligible when experimental context matches	Health Canada SBD 3.3.2 pharmacokinetics manual extraction · human · serum	Result: Interval measurement · Molecular form: ATLPF0028678 · Dose/window: lanreotide 12-60 ng/mL · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

5 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeClearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance5 records · 0 matched-context · 5 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Age has no effect on clearance of lanreotide based on population PK analysis in patients with GEP-NET which included 122 patients aged 65 to 85 years with neuroendocrine tumors.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide age no clearance effect text · Age has no... · Source: Primary reference linked	Reference
2	Observation The effect of hepatic impairment on clearance of lanreotide has not been studied in patients with GEP-NET.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide hepatic impairment clearance not studied t... · Source: Primary reference linked	Reference
3	Observation In subjects with moderate to severe hepatic impairment, a 30% reduction in clearance of lanreotide was observed.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide hepatic impairment clearance reduction tex... · Source: Primary reference linked	Reference
4	Observation Mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment has no effect on clearance of lanreotide in patients with GEP-NET based on population PK analysis which included 106 patients with mild and 59 patients with moderate renal impairment treated with SOMATULINE DEPOT.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment no clearance effect text... · Source: Primary reference linked	Reference
5	Observation An approximate 2-fold decrease in total serum clearance of lanreotide, with a consequent 2-fold increase in half-life and AUC was observed.	Interpret as reported	human · serum	Result: Qualitative or narrative result · Molecular form: ATLPF0028678 · Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment clearance auc change text... · Source: Primary reference linked	Reference

Evidence landscape

20 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

13 evidence records

Distribution / Barrier

2 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

5 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Clearance

Max Concentration

Bioavailability

Area Under Curve

Time To Max Concentration

Plasma Protein Binding

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Clinical / product

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Distribution / Barrier Distribution	Plasma Protein Binding	79-83 %	Interval measurement	Eligible when experimental context matches	Health Canada SBD 3.3.2 pharmacokinetics manual extraction · human · serum	Dose/window: lanreotide 12-60 ng/mL · In vitro serum protein binding study reported in the clinical pharmacokinetics section of the Health Canada SBD.	Reference Primary reference linked
2	Distribution / Barrier Distribution	Volume Of Distribution	16.1 L	Reported point value	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Route: intravenous · Time: steady state · Dose/window: healthy volunteers after intravenous administration · Intrinsic pharmacokinetic parameter after intravenous administration · source de...	Reference Primary reference linked
3	Exposure / Absorption Exposure	Bioavailability	Observation Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.	Qualitative or narrative result	Interpret as reported	Not specified	Route: SC	Source record Primary reference linked
4	Exposure / Absorption Exposure	Time To Max Concentration	<= 1 day <= 86,400 seconds	Upper-bound measurement	Interpret as reported	human	Route: subcutaneous	Reference Primary reference linked
5	Exposure / Absorption Exposure	Time To Max Concentration	<= 1 day <= 86,400 seconds	Upper-bound measurement	Interpret as reported	human	Not specified	Reference Primary reference linked
6	Exposure / Absorption Exposure	Max Concentration	4.3-8.4 ng/mL	Interval measurement	Use only explicitly reported fields	human	Not specified	Reference Primary reference linked
7	Exposure / Absorption Exposure	Max Concentration	3.8 ng/mL	Reported point value	Use only explicitly reported fields	human	Not specified	Reference Primary reference linked
8	Exposure / Absorption Exposure	Max Concentration	5.7 ng/mL	Reported point value	Use only explicitly reported fields	human	Not specified	Reference Primary reference linked
9	Exposure / Absorption Exposure	Max Concentration	7.7 ng/mL	Reported point value	Use only explicitly reported fields	human	Not specified	Reference Primary reference linked
10	Exposure / Absorption Exposure	Bioavailability	73.4 %	Reported point value	Use only explicitly reported fields	human	Route: subcutaneous	Reference Primary reference linked

1–10 / 20

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: 1
Clinical trials: 40
Safety label cues: 5

Linked products1 shown

Lanreotide

SOMATULINE DEPOT

Peptide-product match

Reviewed peptide match

Route / product class

parenteral_other · Injection

Clinical context

40 trial records · 7 exact intervention matches · 9 with results · latest 2026-03-31

Label safety context

Label linked · Contraindications · Adverse reactions · Clinical AE review · Immunogenicity review

View product

Identity & reference map

20 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary4 reference groups

Identity type: identity record
Reported notation: 1
Reference groups: 4
Measurements: 20
ATL peptide ID: ATLPC0027686

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 20

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 20

Different notation

Reported notation does not resolve to the current display sequence.

1 / 20

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

19 / 20

Reported sequence notation

Different1 reference

XCYwKVCT-NH2

Current identity

No sequence representation

Reported names

No distinct human-readable aliases are exposed.

Reference map4 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	ExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +1 more	No reported alias	17 identity 17 evidence
Reference Open	Distribution Plasma Protein Binding	No reported alias	1 identity 1 evidence
Reference Open	Distribution Volume Of Distribution	No reported alias	1 identity 1 evidence
Source record Open	Exposure Bioavailability	No reported alias XCYwKVCT-NH2different	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0027686
Identity type: identity record
ADMET endpoints: 7
Evidence records: 20
Reference groups: 4
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0027686

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0027686' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Feature

Positions

Interpretation

Link

Form-level topology

ATLPF0028678

Disulfide-constrained form. Residue-level connection endpoints are shown separately when available.

Not linked

Value

Analysis use

Assay / model

Result context

Reference

Observation

Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.

Interpret as reported

Not specified

Result: Qualitative or narrative result · Molecular form: not reported · Route: SC · 40 · Lanreotide · exact product name match · field mismatch · Source: Primary reference linked

Source record

78.4 %

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0028678 · Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 120mg · After a single, de... · Source: Primary reference linked